Search by Drug Name or NDC
NDC 13925-0159-01 Lidocaine Hydrochloride 30 mg/g Details
Lidocaine Hydrochloride 30 mg/g
Lidocaine Hydrochloride is a TOPICAL CREAM in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Seton Pharmaceuticals. The primary component is LIDOCAINE HYDROCHLORIDE.
Product Information
| NDC | 13925-0159 |
|---|---|
| Product ID | 13925-159_48101549-c776-4fe3-afb3-457c5bda400f |
| Associated GPIs | 90850060103730 |
| GCN Sequence Number | 007407 |
| GCN Sequence Number Description | lidocaine HCl CREAM (G) 3 % TOPICAL |
| HIC3 | Q5H |
| HIC3 Description | TOPICAL LOCAL ANESTHETICS |
| GCN | 30480 |
| HICL Sequence Number | 001478 |
| HICL Sequence Number Description | LIDOCAINE HCL |
| Brand/Generic | Generic |
| Proprietary Name | Lidocaine Hydrochloride |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Lidocaine Hydrochloride |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | CREAM |
| Route | TOPICAL |
| Active Ingredient Strength | 30 |
| Active Ingredient Units | mg/g |
| Substance Name | LIDOCAINE HYDROCHLORIDE |
| Labeler Name | Seton Pharmaceuticals |
| Pharmaceutical Class | Amide Local Anesthetic [EPC], Amides [CS], Antiarrhythmic [EPC], Local Anesthesia [PE] |
| DEA Schedule | n/a |
| Marketing Category | UNAPPROVED DRUG OTHER |
| Application Number | n/a |
| Listing Certified Through | 2023-12-31 |
Package
Package Images
NDC 13925-0159-01 (13925015901)
| NDC Package Code | 13925-159-01 |
|---|---|
| Billing NDC | 13925015901 |
| Package | 1 TUBE in 1 CARTON (13925-159-01) / 28.35 g in 1 TUBE |
| Marketing Start Date | 2011-06-20 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 0.76449 |
| Pricing Unit | GM |
| Effective Date | 2024-01-17 |
| NDC Description | LIDOCAINE 3% CREAM |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 4, 5 |
| Classification for Rate Setting | G |
| As of Date | 2024-02-21 |
Standard Product Labeling (SPL)/Prescribing Information SPL 1c0abe84-5404-404e-b882-e910e4d43ffb Details
DESCRIPTION:
INACTIVE INGREDIENTS:
CLINICAL PHARMACOLOGY:
MECHANISM OF ACTION:
Lidocaine 3% Cream releases lidocaine from a mild acidic vehicle to stabilize the neuronal membrane by inhibiting the ionic fluxes required for initiation and conduction of impulses, thereby effecting local anesthetic action. A mild acidic vehicle lowers pH to increase protection against alkaline irritations and to provide a favorable environment for healing.
Lidocaine is chemically designated as acetamide, 2- (diethylamino)-N-(2,6-dimethylphenyl), and has the following structure.
PHARMACOKINETICS:
Lidocaine may be absorbed following topical administration to mucous membranes, its rate and extent of absorption depending upon the specific site of application, duration of exposure, concentration and total dosage. In general, the rate of absorption of local anesthetic agents following topical application occurs most rapidly after intratracheal administration. Lidocaine is also well-absorbed from the gastrointestinal tract, but little intact drug appears in the circulation because of biotransformation in the liver.
Lidocaine is metabolized rapidly by the liver and metabolites and unchanged drug are excreted by the kidneys. Biotransformation includes oxidative N-dealkylation, ring hydroxylation, cleavage of the amide linkage and conjugation. N-dealkylation, a major pathway of biotransformation, yields the metabolites monoethylglycinexylidide and glycinexylidide. The pharmacological/ toxicological actions of these metabolites are similar to, but less potent than, those of lidocaine. Approximately 90% of lidocaine administered is excreted in the form of various metabolites and less than 10% is excreted unchanged. The primary metabolite in urine is a conjugate of 4-hydroxy-2, 6-dimethylaniline. The plasma binding of lidocaine is dependent on drug concentration, and the fraction bound decreases with increasing concentration. At concentrations of 1 to 4 g of free base per mL, 60 to 80 percent of lidocaine is protein bound. Binding is also dependent on the plasma concentration of the alpha-1-acid glycoprotein. Lidocaine crosses the blood-brain and placental barriers, presumably by passive diffusion. Studies of lidocaine metabolism following intravenous bolus injections have shown that the elimination half-life of this agent is typically 1.5 to 2 hours. Because of the rapid rate at which lidocaine is metabolized, any condition that affects liver function may alter lidocaine kinetics. The half-life may be prolonged two-fold or more in patients with liver dysfunction. Renal dysfunction does not affect lidocaine kinetics, but may increase the accumulation of metabolites. Factors such as acidosis and the use of CNS stimulants and depressants affect the CNS levels of lidocaine required to produce overt systemic effects. Objective adverse manifestations become increasingly apparent with increasing venous plasma levels above 6 g free base per mL. In the rhesus monkey, arterial blood levels of 18-21 g/mL have been shown to be threshold for convulsive activity.
INDICATIONS:
CONTRAINDICATIONS:
WARNINGS:
For external use only. Not for ophthalmic use.
Methemoglobinemia
Cases of methemoglobinemia have been reported in association with local anesthetic use. Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended.
Signs and symptoms of methemoglobinemia may occur immediately or may be delayed some hours after exposure and are characterized by a cyanotic skin discoloration and abnormal coloration of the blood. Methemoglobin levels may continue to rise; therefore, immediate treatment is required to avert more serious central nervous system and cardiovascular adverse effects, including seizures, coma, arrhythmias, and death. Discontinue [the use of this product] and any other oxidizing agents. Depending on the severity of the symptoms, patients may respond to supportive care, i.e., oxygen therapy, hydration. More severe symptoms may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen.
DRUG INTERACTIONS:
Patients that are administered local anesthetics may be at increased risk of developing methemoglobinemia when concurrently exposed to the following oxidizing agents:
| Class | Examples |
| Nitrates/Nitrites | nitroglycerin, nitroprusside, nitric oxide, nitrous oxide |
| Local anesthetics | benzocaine, lidocaine, bupivacaine, mepivacaine, tetracaine, prilocaine, procaine, articaine, ropivacaine |
| Antieoplastic agents | cyclophosphamide, flutamide, rasburicase, ifosfamide, hydroxyurea |
| Antibiotics | dapsone, sulfonamides, nitrofurantoin, para-aminosalicyclic acid |
| Antimalarials | chloroquine, primaquine |
| Anticonvulsants | phenytoin, sodium valproate, phenobarbital |
| Other drugs | acetaminophen, metoclopramide, sulfa drugs (i.e., sulfasalazine), quinine |
PATIENT COUNSELING INFORMATION:
Inform patients that use of local anesthetics may cause methemoglobinemia, a serious condition that must be treated promptly. Advise patients or caregivers to stop use and seek immediate medical attention if they or someone in their care experience the following signs or symptoms: pale, gray, or blue colored skin (cyanosis); headache; rapid heart rate; shortness of breath; lightheadedness; or fatigue.
PRECAUTIONS:
CARCINOGENESIS, MUTAGENESIS AND IMPAIRMENT OF FERTILITY:
USE IN PREGNANCY:
Teratogenic Effects; Pregnancy Category B:
Reproduction studies have been performed for lidocaine in rats at doses up to 6.6 times the human dose and have revealed no evidence of harm to the fetus caused by lidocaine. There are, however, no adequate and well-controlled studies in pregnant women. Animal reproduction studies are not always predictive of human response. General consideration should be given to this fact before administering lidocaine to women of childbearing potential, especially during early pregnancy when maximum organogenesis takes place.
NURSING MOTHERS:
PEDIATRIC USE:
ADVERSE REACTIONS:
DOSAGE AND ADMINISTRATION:
HOW SUPPLIED:
STORAGE AND HANDLING SECTION
KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.
All prescriptions using this product shall be pursuant to state statutes as applicable. This is not an Orange Book product. This product may be administered only under a physician’s supervision. There are no implied or explicit claims on the therapeutic equivalence.
Store at 25ºC (77ºF); excursions permitted to 15º-30ºC (59º-86º F). See USP Controlled Room Temperature. Protect from freezing.
Marketed by:
Seton Pharmaceuticals
Manasquan, NJ 08736
1-800-510-3401
Iss. 01/19
1900008
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
INGREDIENTS AND APPEARANCE
| LIDOCAINE HYDROCHLORIDE
lidocaine hydrochloride cream |
||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||
| Labeler - Seton Pharmaceuticals (828898002) |
| Registrant - Seton Pharmaceuticals (828898002) |